Literature DB >> 25932136

Association of MYOC and APOE promoter polymorphisms and primary open-angle glaucoma: a meta-analysis.

Hui Guo1, Minghao Li2, Zhe Wang2, Qiji Liu3, Xinyi Wu1.   

Abstract

BACKGROUND: Primary open-angle glaucoma (POAG) is the most common form of glaucoma with a genetic predisposition. The relationship between polymorphisms in MYOC or APOE promoter region and POAG has been addressed in many case-control studies, but the published results were not consistent.
METHODS: A meta-analysis assessing the association between five single nucleotide polymorphisms (SNPs) (in MYOC promoter: rs12035719 and rs2075648; in APOE promoter: rs405509, rs769446 and rs449647) and the risk of POAG was performed based on included studies from literature research. In fixed effect model or random effect model, the Mantel-Haenszel (M-H) pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the genetic association. Stratification analysis was also conducted to test the association within Asian or Caucasian populations.
RESULTS: Twenty five case-control studies within multiple populations were identified and no publish bias was observed. Significant association was detected between POAG risk and MYOC rs2075648 in Caucasian (GA+AA vs. GG, OR=0.587, 95% CI=0.437-0.788, P < 0.001). For other SNPs and in other ethnic populations, no statistic evidence was detected for significant association between them and the development of POAG.
CONCLUSIONS: This meta-analysis suggested a genetic association between one of MYOC polymorphism (rs2075648) and the risk of POAG only in Caucasian population. The significant heterogeneity for this locus might imply the different POAG genetic basis among different populations.

Entities:  

Keywords:  APOE; MYOC; glaucoma; meta-analysis; polymorphism

Year:  2015        PMID: 25932136      PMCID: PMC4402783     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  72 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Association of a single nucleotide polymorphism in the TIGR/MYOCILIN gene promoter with the severity of primary open-angle glaucoma.

Authors:  E Colomb; T D Nguyen; A Béchetoille; J C Dascotte; F Valtot; A P Brézin; M Berkani; B Copin; L Gomez; J R Polansky; H J Garchon
Journal:  Clin Genet       Date:  2001-09       Impact factor: 4.438

3.  Myocilin mt1 promoter polymorphism in Turkish patients with primary open angle glaucoma.

Authors:  Riza Köksal Ozgül; Banu Bozkurt; Serkan Orcan; Burçin Bulur; Sefayet Bagiyeva; Murat Irkeç; Ay Ogüş
Journal:  Mol Vis       Date:  2005-11-02       Impact factor: 2.367

4.  Myocilin mt.1 gene promoter single nucleotide polymorphism (-1000C>G) in Brazilian patients with primary open angle glaucoma.

Authors:  Niro Kasahara; Cristiano Caixeta-Umbelino; Maurício D Paolera; Mylene N Rocha; Flávio Richeti; José P C Vasconcellos; Ralph Cohen; Vital P Costa; Carlos A Longui; Murilo R Melo; Mônica B Melo
Journal:  Ophthalmic Genet       Date:  2010-12-21       Impact factor: 1.803

5.  Promoter mutations of myocilin gene in Japanese patients with open angle glaucoma including normal tension glaucoma.

Authors:  R Suzuki; Y Hattori; K Okano
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

6.  Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma.

Authors:  Seongsoo Sohn; Wonhee Hur; Young Ran Choi; Yun Shin Chung; Chang-Seok Ki; Changwon Kee
Journal:  Br J Ophthalmol       Date:  2010-05       Impact factor: 4.638

7.  Mutations in MYOC gene of Indian primary open angle glaucoma patients.

Authors:  Arijit Mukhopadhyay; Moulinath Acharya; Saibal Mukherjee; Jharna Ray; Sumit Choudhury; Mita Khan; Kunal Ray
Journal:  Mol Vis       Date:  2002-11-15       Impact factor: 2.367

8.  Investigation of founder effects for the Thr377Met Myocilin mutation in glaucoma families from differing ethnic backgrounds.

Authors:  Alex W Hewitt; John R Samples; R Rand Allingham; Irma Järvelä; George Kitsos; Subbaiah R Krishnadas; Julia E Richards; Paul R Lichter; Michael B Petersen; Periasamy Sundaresan; Janey L Wiggs; David A Mackey; Mary K Wirtz
Journal:  Mol Vis       Date:  2007-03-28       Impact factor: 2.367

9.  Alzheimer's disease and primary open-angle glaucoma: is there a connection?

Authors:  Fani Tsolaki; Eleni Gogaki; Sotiria Tiganita; Christina Skatharoudi; Chrysanthi Lopatatzidi; Fotios Topouzis; Magdalini Tsolaki
Journal:  Clin Ophthalmol       Date:  2011-06-28

10.  Role of CYP1B1, MYOC, OPTN, and OPTC genes in adult-onset primary open-angle glaucoma: predominance of CYP1B1 mutations in Indian patients.

Authors:  Arun Kumar; Manjunath G Basavaraj; Santosh K Gupta; Imteyaz Qamar; Abdullah Mahmood Ali; Vineeta Bajaj; T K Ramesh; D Ravi Prakash; Jyoti S Shetty; Syril K Dorairaj
Journal:  Mol Vis       Date:  2007-04-30       Impact factor: 2.367

View more
  4 in total

Review 1.  Asian Race and Primary Open-Angle Glaucoma: Where Do We Stand?

Authors:  Aditya Belamkar; Alon Harris; Francesco Oddone; Alice Verticchio Vercellin; Anna Fabczak-Kubicka; Brent Siesky
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

2.  The SPARC-related modular calcium binding protein 2 (SMOC2) gene polymorphism in primary glaucoma: a case-control study.

Authors:  Najwa Al-Dabbagh; Hamoud Al-Shahrani; Nourah Al-Dohayan; Md Mustafa; Misbahul Arfin; Abdulrahman K Al-Asmari
Journal:  Clin Ophthalmol       Date:  2017-03-20

Review 3.  Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects.

Authors:  Nitin Chitranshi; Yogita Dheer; Mojdeh Abbasi; Yuyi You; Stuart L Graham; Vivek Gupta
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

4.  Indistinguishable gene expression between healthy eyes and eyes with unilateral exfoliative glaucoma.

Authors:  Marcelo Ayala; Filip Cuklev
Journal:  Clin Ophthalmol       Date:  2018-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.